{"name":"Beijing InnoCare Pharma Tech Co., Ltd.","slug":"beijing-innocare-pharma-tech-co-ltd","ticker":"","exchange":"","domain":"beijinginnocarepharmatech.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"ICP-022","genericName":"ICP-022","slug":"icp-022","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"ICP-488","genericName":"ICP-488","slug":"icp-488","indication":"Acute myeloid leukemia with FLT3 mutations","status":"phase_3"},{"name":"ICP-488 Tablets","genericName":"ICP-488 Tablets","slug":"icp-488-tablets","indication":"Non-small cell lung cancer with EGFR mutations","status":"phase_3"},{"name":"Orelabrutinib + R-CHOP","genericName":"Orelabrutinib + R-CHOP","slug":"orelabrutinib-r-chop","indication":"Treatment of relapsed or refractory mantle cell lymphoma","status":"phase_3"},{"name":"Orelabrutinib and R-CHOP","genericName":"Orelabrutinib and R-CHOP","slug":"orelabrutinib-and-r-chop","indication":"Non-Hodgkin lymphoma","status":"phase_3"},{"name":"Placebo + R-CHOP","genericName":"Placebo + R-CHOP","slug":"placebo-r-chop","indication":"B-cell non-Hodgkin lymphoma (specific subtype not specified in available information)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ICP-189","genericName":"ICP-189","slug":"icp-189","indication":"Other","status":"phase_1"},{"name":"ICP-322","genericName":"ICP-322","slug":"icp-322","indication":"Other","status":"phase_2"},{"name":"ICP-332","genericName":"ICP-332","slug":"icp-332","indication":"Other","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ICP-332 Tablets","genericName":"ICP-332 Tablets","slug":"icp-332-tablets","indication":"Hematologic malignancies (phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"ICP-189","genericName":"ICP-189","slug":"icp-189","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ICP-022","genericName":"ICP-022","slug":"icp-022","phase":"phase_3","mechanism":"ICP-022 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Mantle cell lymphoma (MCL)"],"catalyst":""},{"name":"ICP-322","genericName":"ICP-322","slug":"icp-322","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ICP-332","genericName":"ICP-332","slug":"icp-332","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ICP-332 Tablets","genericName":"ICP-332 Tablets","slug":"icp-332-tablets","phase":"phase_3","mechanism":"ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","indications":["Hematologic malignancies (phase 3 development)"],"catalyst":""},{"name":"ICP-488","genericName":"ICP-488","slug":"icp-488","phase":"phase_3","mechanism":"ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.","indications":["Acute myeloid leukemia with FLT3 mutations"],"catalyst":""},{"name":"ICP-488 Tablets","genericName":"ICP-488 Tablets","slug":"icp-488-tablets","phase":"phase_3","mechanism":"ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.","indications":["Non-small cell lung cancer with EGFR mutations"],"catalyst":""},{"name":"Orelabrutinib + R-CHOP","genericName":"Orelabrutinib + R-CHOP","slug":"orelabrutinib-r-chop","phase":"phase_3","mechanism":"Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, and R-CHOP is a chemotherapy regimen that includes rituximab, cyclophosphamide, doxorubicin, and prednisone.","indications":["Treatment of relapsed or refractory mantle cell lymphoma"],"catalyst":""},{"name":"Orelabrutinib and R-CHOP","genericName":"Orelabrutinib and R-CHOP","slug":"orelabrutinib-and-r-chop","phase":"phase_3","mechanism":"Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells.","indications":["Non-Hodgkin lymphoma"],"catalyst":""},{"name":"Placebo + R-CHOP","genericName":"Placebo + R-CHOP","slug":"placebo-r-chop","phase":"phase_3","mechanism":"This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas.","indications":["B-cell non-Hodgkin lymphoma (specific subtype not specified in available information)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5NZkZlc3l0VTRHTkZIcEE1NGlUTDhHY2lnbGVtMzNSSGY2YVdpUnRYaFVPWnNGaE9BR1dsZkVCTS1Bb2lub3oyM1BIckNuRE0xbEZRLWNlSEpiamo2QXN0VEUtUGxkMWlBeDdmZw?oc=5","date":"2026-03-30","type":"pipeline","source":"sg.finance.yahoo.com","summary":"CANbridge Pharmaceuticals Inc. (1228.HK) Analyst insights, Price targets and Recommendations - sg.finance.yahoo.com","headline":"CANbridge Pharmaceuticals Inc. (1228.HK) Analyst insights, Price targets and Recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPNC1HXzBfbVpNVG83WXQ5ekVkQmRDUXU4Tkd1WVBGNnhJRTgweVBlUWNna2IwVWZKWUdvVk1UbDlKa0Qybm5FRDZDc2pJbDhhNl9XSDA2eHVSVkdOX0VQVHBpcEtVbFRmaVZlM1NkNElxLV9UUmVxVlBYY3RHR1hBRHp1SS0zMTB3anhabGlCN2JtZzZYX000N3FsT2o?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With - openPR.com","headline":"B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxORjhveFB0Z2ttQ25jY21vOVhUdHdDM0N6SXJaSEN5cWxqMEY4dG5LbVQyT3FFNTF6WGRCZ29ocDIyTG5KSXNsNzJPaDdBbl83RTZsZ2lWYVNneEdQOE1kWVBHblFhRlBwMFM5cGU3Zm9fUlBfeWNyRWVCUjdpUG9CWFFhWUZTRDZ6aV9IY2NIblFEUQ?oc=5","date":"2026-03-19","type":"pipeline","source":"BioWorld News","summary":"Innocare presents new VAV1 degradation inducers - BioWorld News","headline":"Innocare presents new VAV1 degradation inducers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNSnZmMjNkMTByNTVxRllwNE9nb01uY1otQ3lBbUJEc1gxai1oZGtDc2Q4eERLWnFoYkdjWGRkVkQyMEcxOUNzdFVBZEhIaGx0eXlraUloMXhtMDJIQkVNTXVZZUd5UXp5M3hrQnBJa3JhSUF3cHM1V1pWRW1MVGFvUURjSWQtYU9JWDJtMjBaaUNkdjNtUlBuczFxbjkxMWoyOWc?oc=5","date":"2026-02-09","type":"pipeline","source":"BioWorld News","summary":"Innocare’s VAV1 degrader ICP-538 cleared for clinic in China - BioWorld News","headline":"Innocare’s VAV1 degrader ICP-538 cleared for clinic in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5KQWRnUzNaSjNEWHpPdl9iS0lUMC1ITURZajd2X21LQ2Q5TDhxUzRXcDlQUUxqVGFRSks0RnBkVWdERTRXQkpndWFlTEhCbXBuX1Qw?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"AVBP Stock Price, News & Analysis - Stock Titan","headline":"AVBP Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNazhhbDlwWG1EaUN4V0RLSWhtc1hOai1zMWtxLXBIYUFWNDZORmhQekRtZEZCLTdDRWxyR3FmWWRieTdlZEpZc2ljTUtPVmk5bjJfTFJNQWh3cjdlNmllWmdFTEI0N2V2ZlBfdkdUa2pNNXY2TU5tNlYzVWxUQUtJWXdId3hJYk0zazNqc1JGN0tUSlVoVEV1U2dkRnl0Z0pza0ZFdFVlQ2NIS28yU2lkQnZIYWZ1TU10LWhTM3MtMTF0bHVHQjYwMGgyQ2pRRVhydEFYTUpFVUsyUnVkNVZpNnhtLVNTX25oNmxBTGNzajIyOHI2bWRDaVVHZEdxUQ?oc=5","date":"2025-01-20","type":"deal","source":"Business Wire","summary":"InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02 - Business Wire","headline":"InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOMUt5VjhPX09yMHNkRWV2cV9NYVJpb3FSSlB0RE5leHFZSkJLeUFGSVAwQnI2dHVtTTFnbmh3R09Rb2hfYkQ0R1dKM3FON19aZ3dqSEZYZnBWb2JDTUlXdFVTeUhTTTlGMEJfVnd4VmdSUU9OU3VHb2JaR3o2cERBUEV3?oc=5","date":"2024-04-27","type":"regulatory","source":"China Daily - Global Edition","summary":"InnoCare Pharma Limited expects multiple drug products to reach approval - China Daily - Global Edition","headline":"InnoCare Pharma Limited expects multiple drug products to reach approval - China Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQM2ZJZjQzdlV3VGNDUndBekNSVEdVUnVVRTRILTMwVWdlS2UwZVVicUt4QlBseXJkZjY2MzRKRS1CRmljTWZ6UFZHVWhjaHN4ZHhkdGhFNlFPNjVTWDJRT2EySkJGZzdmSmkxdkRsRXJqdTE5UzNTbW9xU0tHMndOZnNwT0RQY2dFMHFOX1AwODh6UjQ?oc=5","date":"2019-07-29","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 10 Young Companies in the Money, January–July 2019 - Genetic Engineering and Biotechnology News","headline":"Top 10 Young Companies in the Money, January–July 2019","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_1":1,"phase_3":7,"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}